The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Compounds · Repair & healing peptides · continued

Why the absence of controlled human data on BPC-157 matters more than people admit posts 61–67

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.

W
WendelboeTL2Member17 Jul 2026#61
b.vestergaard, post #21: Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound. Go to post

This follows post #58 rather than contradicting it.

Why plausible mechanism is not evidence of effect: a mechanism that is chemically or biologically plausible can fail in practice for dozens of reasons — bioavailability, off-target effects, metabolism, clearance, or simply that the mechanism does not do what the theory predicts in a living system. Plausibility is necessary for hope but not sufficient for evidence.

0 likes in reply to #21 11d
FY
f.yildizTL2 Moderator19 Jul 2026#62

I read post #60 twice before replying, because I had assumed the opposite.

Reading a preclinical wound-healing model: the model shows whether a mechanism is plausible in a specific context. It does not show magnitude of effect in humans, does not show safety profile in humans, and does not show whether the effect survives in a more complex biological system. That is not a criticism of preclinical work — it is what preclinical work is for.

1 like 9d
GP
g.pemberton_ukTL3Regional · UK20 Jul 2026#63

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

10 likes 8d
AV
ai.vukovicTL2 Moderator22 Jul 2026#64

TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The two are routinely conflated in supplier documentation and in the literature. Evidence about the full protein does not automatically apply to the fragment.

22 likes 6d
ST
stopper_traceTL2Member23 Jul 2026#65
owen.brady, post #29: Picking up post #26: that is the part I would want checked first. BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut,… Go to post

Picking up post #62: that is the part I would want checked first.

Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.

0 likes in reply to #29 4d
NH
n.hartmannTL2 Moderator25 Jul 2026 · edited#66

Why plausible mechanism is not evidence of effect: a mechanism that is chemically or biologically plausible can fail in practice for dozens of reasons — bioavailability, off-target effects, metabolism, clearance, or simply that the mechanism does not do what the theory predicts in a living system. Plausibility is necessary for hope but not sufficient for evidence.

2 likes 3d
N
NHuddlestonTL1Member27 Jul 2026#67

Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.

15 likes 1d

Suggested topics

TopicParticipantsRepliesViewsActivity
Stability of BPC-157 in solution: what has been measured
Stability of BPC-157 in solution: what has been measured — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with FLOW ( N Engl J Med , 2024) and finding the…
AKEFSS 2 805 30d
Reading a preclinical wound-healing model and its relevance to a human tendon
On the subject in the title: Reading a preclinical wound-healing model and its relevance to a human tendon Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support…
PMDAPFFRD+149 160 3.3k 20mo
Why plausible mechanism is not evidence of effect — one year on
The question in the title: Why plausible mechanism is not evidence of effect — one year on I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read…
FNPNMBUCIL+3 7 3.6k 13mo
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet ,…
FAKLSLAS+50 55 7.8k 2d
Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset
Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016)…
RDSTGBTNAA+64 69 27k 4mo

Related topics — sharing the tags needs a source, BPC-157, preprint

TopicParticipantsRepliesViewsActivity
The "under review" status pill and when a moderator applies it — a second dataset
The "under review" status pill and when a moderator applies it — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021)…
LVARMISLPM+50 54 1.4k 11mo
Ipamorelin selectivity claims and where they came from — a second dataset
Posting this under the heading it deserves: Ipamorelin selectivity claims and where they came from — a second dataset Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021)…
TIDCM 2 27k 14mo
Melanocortin agonists: mechanism and the documented adverse profile
Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-2 ( Lancet , 2023) and…
APAWCEBWGR+7 11 5.5k 20mo
Follow-up: Evidence quality in the secretagogue literature: an honest assessment
On the subject in the title: Evidence quality in the secretagogue literature: an honest assessment Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with LEADER ( N Engl J Med…
BSHRTMNCI+20 24 18k 4mo
The retatrutide phase 2 obesity paper, read closely
Posting this under the heading it deserves: The retatrutide phase 2 obesity paper, read closely Everything below is what sits behind that. Session topic: STEP 8 ( JAMA , 2022). Please read it before posting;…
KTDEF 2 65k 10mo